Merck Animal Health to Present Important New Data at the 6th European Symposium of Porcine Health Management

Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2) and Reproduction Health Management Data to be Presented

SUMMIT, NEW JERSEY, April 30, 2014 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) will present results from more than 20 studies at the 6th European Symposium of Porcine Health Management in Sorrento, Italy from May 7-9, 2014. The studies are mainly focused on Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus type 2 (PCV2) and Reproduction Health Management.

“Merck Animal Health, through our commitment to the Science of Healthier Animals™, is dedicated to providing veterinarians and pig producers with comprehensive solutions to manage the health of their herds,” said Narciso Bento, Global Swine Business Merck Animal Health. “At ESPHM, we are pleased to share new state-of-the-art data that will help veterinarians and producers be more efficient and improve the management of the most serious and costly problems and diseases affecting pigs today.”

Abstracts selected for oral and poster presentations are as follows:

Oral Presentation


  • Return on investment of fixed time insemination (Thursday, May 8; 16:45-17:00)

Poster Presentations

Viral Diseases

  • Case report of a PRRSV infection via semen and clinical signs in PRRSV vaccinated and unvaccinated herds (P69)
  • Efficacy of piglet’s PRRS vaccination to reduce viral transmission in the nursery (P71)
  • Characterization of the humoral immune response elicited by vaccination with PORCILIS® PRRS administered by different routes (P72)
  • Control of PCV2 subclinical infection: ROI comparison of 2 one dose vaccines in a high health status pig herd (P74)

Herd Health Management

  • Effects of management strategies on abortion episodes and PRRSV circulation in an endemically infected breeding farm (P96)
  • Evaluation of pig performance and lung lesions score in the slaughterhouse of pigs vaccinated with M+PAC or competitor vaccine (P98)
  • Impact of vaccination with a modified live PRRS vaccine in a continuous flow weaner to finisher unit in the UK (P105)
  • Study on the relationship between seroprevalence of Ascaris suum in fatteners, farm management factors and production parameters (P108)
  • Comparative clinical study of PORCILIS  M Hyo ID Once, an intradermal Mycoplasma hyopneumoniae (M. h.) vaccine, versus Suvaxyn® M.Hyo Mono (P117)
  • Comparative clinical study of PORCILIS  M Hyo ID Once, an intradermal Mycoplasma hyopneumoniae (M. h.) vaccine, versus Stellamune® Mono (P118)
  • Comparative clinical study of PORCILIS  M Hyo ID Once, an intradermal Mycoplasma hyopneumoniae (M. h.) vaccine, versus Ingelvac® M. Hyo (P119)
  • Prevalence of nematodes in loose housed industrialized sows from a pig practice in Funen, Denmark (P40)

Bacterial Diseases

  • Use of ResPig™ to monitor efficacy of different vaccination strategies to control mycoplasma hyopneumonia infection (P167)
  • Practical approach of upper respiratory tract problems of weaned piglets and the effect of passive Atrophic Rhinitis (AR) immunization on clinical symptoms and antibiotic use (P178)
  • Safety of the intradermal vaccination against Mycoplasma hyopneumoniae using the needle-free IDAL device (P186)
  • Gilts and sows PCV2 re-vaccination at mating increases the homogeneity and the titres of antibodies at farrowing and the passive transfer to the piglets, but does not affect the frequency of IFN-y secreting cells (P215)

Immunology and Vaccinology

  • Intradermal vaccination of piglets against Mycoplasma hyopneumoniae with the needle-free IDAL device; clinical evaluation (P217)
  • Control of pneumonia in a finishing farm following two different Mycoplasma hyopneumonia vaccination strategies (P187)


  • A case report of single dose fixed time insemination (P237)
  • Effective treatment of polycystic ovarian degeneration in gilts and sows with Altrenogest (REGUMATE®) – First results (P239)
  • Single fixed time insemination in multiparous sows with an injection of gonadotropin-releasing hormone agonist (RECEPTAL®) (P240)
  • The effect of correct gilt management on reproduction parameters (P241)
  • A single fixed time insemination following ovulation induction allows successful breeding of gilts and sows (P245)

About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals.

It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (